Vitrolife
Vitrolife AB, headquartered in Sweden, is a leading player in the reproductive health industry, specialising in products and services for assisted reproductive technology (ART). Founded in 1994, the company has established a strong presence in key operational regions, including Europe, North America, and Asia. Vitrolife is renowned for its innovative solutions, including culture media, cryopreservation products, and laboratory equipment designed to enhance the success rates of IVF treatments. Their commitment to quality and research has positioned them as a trusted partner for fertility clinics worldwide. With a focus on advancing reproductive medicine, Vitrolife continues to achieve significant milestones, solidifying its reputation as a pioneer in the field.
DitchCarbon Score
How does Vitrolife's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Vitrolife's score of 54 is higher than 70% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Vitrolife's reported carbon emissions
In 2024, Vitrolife reported total carbon emissions of approximately 20,000,000 kg CO2e, with significant contributions from Scope 1, Scope 2, and Scope 3 emissions. Specifically, Scope 1 emissions were about 742,000 kg CO2e, while Scope 2 emissions (market-based) totalled around 1,242,000 kg CO2e. The majority of emissions stemmed from Scope 3, which accounted for approximately 18,503,000 kg CO2e, with notable categories including upstream transportation and distribution (about 5,970,000 kg CO2e) and purchased goods and services (approximately 4,109,000 kg CO2e). Vitrolife has set ambitious near-term targets to reduce its greenhouse gas emissions. The company aims to achieve a 42% reduction in absolute Scope 1 and Scope 2 emissions by 2030, using 2023 as the baseline year. Additionally, it targets a 51.6% reduction in Scope 3 emissions per million SEK value added, covering categories such as business travel and waste generated in operations, also by 2030. These targets are aligned with the Science Based Targets initiative (SBTi) and are designed to support the global effort to limit warming to 1.5°C. Overall, Vitrolife's commitment to reducing its carbon footprint reflects a proactive approach to sustainability within the healthcare equipment and supplies sector, with a focus on both operational and supply chain emissions.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2023 | 2024 | |
|---|---|---|---|---|
| Scope 1 | 515,000 | 000,000 | 000,000 | 000,000 |
| Scope 2 | 702,000 | 000,000 | 0,000,000 | 0,000,000 |
| Scope 3 | 1,199,000 | 0,000,000 | 00,000,000 | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Vitrolife is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
